促红细胞生成素刺激剂治疗低危和中危-1型骨髓增生异常综合征的临床有效性与安全性:一项系统性文献综述
该系统性文献综述纳入53篇文章 reporting 35项研究,评估促红细胞生成素刺激剂(ESA)治疗低危/中危-1型骨髓增生异常综合征(MDS)贫血的疗效、生活质量和安全性。ESA初治者红系缓解率45-73%,既往ESA暴露者25-75%,缓解持续时间一致改善;比较研究显示向急性髓系白血病进展相似,多项研究显示总生存和生活质量改善,安全性顾虑有限。分析确认ESA治疗应作为大多数缺乏5q缺失的低危MDS患者贫血的首选一线治疗。
要点
- ESA初治患者红系缓解率45-73%,既往ESA暴露者25-75%。
- 比较研究显示向急性髓系白血病进展相似,多项研究显示总生存和生活质量改善。
- ESA治疗应作为大多数缺乏5q缺失的低危MDS患者贫血的首选一线治疗。
核心结论
- 分析确认ESA治疗应作为大多数缺乏5q缺失的低危MDS患者贫血的首选一线治疗。
研究设计与样本
- 系统性文献综述,检索随机和非随机前瞻性研究,报告临床疗效/有效性、患者报告的生活质量和安全性。
- 针对达贝泊汀α特别扩展纳入回顾性研究,并评估完成间接网络Meta分析比较依泊汀和达贝泊汀α的可行性。
- 共纳入53篇文章,报告35项研究。
主要发现
- ESA初治患者红系缓解率45-73%,既往ESA暴露者25-75%,缓解持续时间一致改善。
- 比较研究显示向急性髓系白血病进展相似,多项研究显示总生存和生活质量改善。
- 安全性顾虑有限。
关键数值与推荐
- ESA初治患者红系缓解率45-73%。
- 既往ESA暴露者红系缓解率25-75%。
临床怎么用
- ESA治疗应作为大多数缺乏5q缺失的低危MDS患者贫血的首选一线治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients with lower-risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis-stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly used and recommended by clinical guidelines. To better understand the evidence available on the use of ESAs for anaemia in lower-risk MDS, we conducted a systematic literature review to identify randomized and nonrandomized prospective studies reporting on clinical efficacy/effectiveness, patient-reported quality of life (QoL), and safety. We extended our review to include retrospective studies for darbepoetin alfa specifically and to ascertain the feasibility of completing an indirect network meta-analysis comparing epoetin and darbepoetin alfa. Overall, 53 articles reporting on 35 studies were included. The studies indicated a clinical benefit of ESAs, with benefits observed across key clinical outcomes. ESAs showed consistent improvement in erythroid response rates (ESA-naïve, 45-73%; previous ESA exposure, 25-75%) and duration of response. Comparative studies demonstrated similar progression to acute myeloid leukaemia and several showed improved overall survival and QoL. Limited safety concerns were identified. This analysis confirmed ESA therapy should be the foremost first-line treatment of anaemia in most patients with lower-risk MDS who lack the 5q deletion.
引用
- Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2018. PMID: 30549002. doi:10.1111/bjh.15707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。